Eisai's chief executive has mapped out a three-prong strategy for marketing the new diet drug Belviq in early 2013. Haruo Naito says Eisai will work on patient education, enhancing disease awareness and collaborations with patient groups as it starts to campaign for insurance coverage. Naito, though, was unwilling to tell Dow Jones what it will charge for the treatment, though some analysts expect to see a price tag of around $3.50 a day. He also said that Eisai is interested in pursuing other deals on oncology, neuroscience and immunology that would be similar to the $325 million acquisition of Morphotek in 2007. StoryLike what you're reading?
Click here to get more news like this delivered to your inbox everyday>>